• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    6/3/24 1:35:22 PM ET
    $BIIB
    $COR
    $CORT
    $GPCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $BIIB alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    PHR PUT TRADE NEUTRAL 06/21/24 $20.00 $570.0K 3.2K 3.1K
    LLY CALL SWEEP BEARISH 06/07/24 $850.00 $87.7K 386 1.2K
    CORT PUT SWEEP BEARISH 06/21/24 $30.00 $101.6K 1.4K 660
    GPCR PUT TRADE NEUTRAL 12/19/25 $50.00 $86.6K 0 571
    HIMS CALL SWEEP BULLISH 01/17/25 $20.00 $42.9K 12.6K 436
    NVAX CALL TRADE BULLISH 01/17/25 $20.00 $116.6K 4.2K 418
    COR PUT SWEEP BEARISH 06/21/24 $230.00 $61.2K 134 301
    BIIB CALL SWEEP BULLISH 06/14/24 $230.00 $26.4K 61 157
    VKTX CALL TRADE BULLISH 06/21/24 $60.00 $26.0K 666 121
    HCA PUT SWEEP BULLISH 06/20/25 $330.00 $27.4K 12 78

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For PHR (NYSE:PHR), we notice a put option trade that happens to be neutral, expiring in 18 day(s) on June 21, 2024. This event was a transfer of 3000 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $570.0K, with a price of $190.0 per contract. There were 3204 open contracts at this strike prior to today, and today 3134 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a call option sweep that happens to be bearish, expiring in 4 day(s) on June 7, 2024. This event was a transfer of 283 contract(s) at a $850.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $87.7K, with a price of $310.0 per contract. There were 386 open contracts at this strike prior to today, and today 1278 contract(s) were bought and sold.

    • Regarding CORT (NASDAQ:CORT), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on June 21, 2024. Parties traded 654 contract(s) at a $30.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $101.6K, with a price of $160.0 per contract. There were 1416 open contracts at this strike prior to today, and today 660 contract(s) were bought and sold.

    • Regarding GPCR (NASDAQ:GPCR), we observe a put option trade with neutral sentiment. It expires in 564 day(s) on December 19, 2025. Parties traded 85 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $86.6K, with a price of $1020.0 per contract. There were 0 open contracts at this strike prior to today, and today 571 contract(s) were bought and sold.

    • For HIMS (NYSE:HIMS), we notice a call option sweep that happens to be bullish, expiring in 228 day(s) on January 17, 2025. This event was a transfer of 90 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $478.0 per contract. There were 12652 open contracts at this strike prior to today, and today 436 contract(s) were bought and sold.

    • Regarding NVAX (NASDAQ:NVAX), we observe a call option trade with bullish sentiment. It expires in 228 day(s) on January 17, 2025. Parties traded 299 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $116.6K, with a price of $390.0 per contract. There were 4211 open contracts at this strike prior to today, and today 418 contract(s) were bought and sold.

    • Regarding COR (NYSE:COR), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on June 21, 2024. Parties traded 153 contract(s) at a $230.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $61.2K, with a price of $400.0 per contract. There were 134 open contracts at this strike prior to today, and today 301 contract(s) were bought and sold.

    • Regarding BIIB (NASDAQ:BIIB), we observe a call option sweep with bullish sentiment. It expires in 11 day(s) on June 14, 2024. Parties traded 44 contract(s) at a $230.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $600.0 per contract. There were 61 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold.

    • For VKTX (NASDAQ:VKTX), we notice a call option trade that happens to be bullish, expiring in 18 day(s) on June 21, 2024. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $520.0 per contract. There were 666 open contracts at this strike prior to today, and today 121 contract(s) were bought and sold.

    • For HCA (NYSE:HCA), we notice a put option sweep that happens to be bullish, expiring in 382 day(s) on June 20, 2025. This event was a transfer of 9 contract(s) at a $330.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $3050.0 per contract. There were 12 open contracts at this strike prior to today, and today 78 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIIB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB
    $COR
    $CORT
    $GPCR

    CompanyDatePrice TargetRatingAnalyst
    HCA Healthcare Inc.
    $HCA
    10/14/2025$470.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    10/14/2025Hold → Buy
    Erste Group
    Biogen Inc.
    $BIIB
    9/25/2025$190.00Buy
    Jefferies
    Eli Lilly and Company
    $LLY
    9/17/2025$830.00Buy → Hold
    Berenberg
    Phreesia Inc.
    $PHR
    9/5/2025$33.00Buy
    DA Davidson
    Novavax Inc.
    $NVAX
    8/28/2025$10.00Buy
    H.C. Wainwright
    Phreesia Inc.
    $PHR
    8/27/2025$36.00Outperform
    Mizuho
    Eli Lilly and Company
    $LLY
    8/27/2025$700.00Reduce → Hold
    HSBC Securities
    More analyst ratings

    $BIIB
    $COR
    $CORT
    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Swisher Daniel N Jr exercised 2,200 shares at a strike of $14.08 and sold $192,588 worth of shares (2,200 units at $87.54) (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    10/15/25 6:31:16 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Chi Michael exercised 900 shares at a strike of $6.82 and sold $52,425 worth of shares (900 units at $58.25) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    10/14/25 4:17:51 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Legal Officer Boughton Soleil sold $143,400 worth of shares (2,637 units at $54.38), decreasing direct ownership by 2% to 161,130 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    10/14/25 4:17:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly confirms date and conference call for third-quarter 2025 financial results announcement

    INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into heal

    10/16/25 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes

    Biomarker data, enhanced therapeutic data and insights will enable biopharmaceutical innovation and physician support through informed decision-making IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansion, IntrinsiQ is now also offering oncology biomarker data, enabling physicians to transition from a generalized treatment approach to precision medicine. This critical data allows physicians to tailor cancer therapies to the individual needs of each patient, helping to optimize treatment outcomes and advance the standard of car

    10/16/25 9:00:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

    Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time  SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2025 after the market close on Wednesday, October 22, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on

    10/15/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    $COR
    $CORT
    $GPCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on HCA with a new price target

    Goldman resumed coverage of HCA with a rating of Buy and set a new price target of $470.00

    10/14/25 8:49:40 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    Eli Lilly upgraded by Erste Group

    Erste Group upgraded Eli Lilly from Hold to Buy

    10/14/25 8:36:03 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Biogen with a new price target

    Jefferies initiated coverage of Biogen with a rating of Buy and set a new price target of $190.00

    9/25/25 8:28:11 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    SEC Filings

    View All

    Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOGEN INC. (0000875045) (Filer)

    10/14/25 4:19:10 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Corcept Therapeutics Incorporated

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    10/14/25 6:02:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NOVAVAX INC (0001000694) (Filer)

    10/7/25 7:00:33 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Leadership Updates

    Live Leadership Updates

    View All

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    HCA Healthcare Presents 2025 Awards of Distinction

    HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today presented its annual HCA Healthcare Awards of Distinction at a ceremony in Nashville, Tennessee. The HCA Healthcare Awards of Distinction—comprising the Frist Humanitarian Award and the Excellence in Nursing Award—are the highest honors HCA Healthcare bestows on employees, physicians and volunteers, recognizing the extraordinary individuals who exemplify the organization's culture and values. The Frist Humanitarian Award recognizes the highest achievements in serving others, and the HCA Healthcare Excellence in Nursing Award recognizes the highest levels of performance in the field of nursing. "The

    9/30/25 4:30:00 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Financials

    Live finance-specific insights

    View All

    Lilly confirms date and conference call for third-quarter 2025 financial results announcement

    INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into heal

    10/16/25 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

    Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time  SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2025 after the market close on Wednesday, October 22, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on

    10/15/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 3, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a missio

    10/13/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIIB
    $COR
    $CORT
    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care